Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01290120 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | completed | Phase 2 | 182 | Northern Italy Leukemia GroupOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT00225212 | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Sep 15, 2014 | clinicaltrials |
| NCT00532259 | CT-011 MAb in DLBCL Patients Following ASCT | completed | Phase 2 | 72 | CureTech LtdINDUSTRY | 3 | Sep 12, 2014 | clinicaltrials |
| NCT01499303 | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | completed | Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 22, 2014 | clinicaltrials |
| NCT00576758 | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 175 | Hoffmann-La RocheINDUSTRY | 17 | Aug 19, 2014 | clinicaltrials |
| NCT00691704 | Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | completed | Phase 2 | 18 | Cristina GasparettoOTHER | 1 | Aug 19, 2014 | clinicaltrials |
| NCT00972959 | Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | completed | Phase 2 | 17 | University of AthensOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00586755 | Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma | completed | Phase 2 | 48 | Duke UniversityOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients(MUNIN) | completed | Phase 2 | 59 | GlaxoSmithKlineINDUSTRY | 1 | Jul 11, 2014 | clinicaltrials |
| NCT00586014 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 91 | Duke UniversityOTHER | 0 | Jul 8, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT01096342 | Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 2 | Jun 18, 2014 | clinicaltrials |
| NCT01283776 | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation(OCTET-CY) | completed | Phase 2 | 11 | University of CologneOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00075881 | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00142116 | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 25 | Steven P. Treon, MD, PhDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00117988 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00302757 | Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00306111 | Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma | completed | Phase 2 | 14 | University Hospital TuebingenOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00514137 | Sunitinib in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00058019 | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00132028 | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00290472 | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01280526 | A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas(Ro-CHOP) | completed | Phase 1 / Phase 2 | 37 | The Lymphoma Academic Research OrganisationOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184080 | Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00872521 | A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma | completed | Phase 2 | 107 | Janssen-Cilag Pty LtdINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT00049036 | Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00398112 | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00402181 | An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 53 | Centocor, Inc.INDUSTRY | 2 | May 14, 2014 | clinicaltrials |
| NCT00303953 | PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 12, 2014 | clinicaltrials |
| NCT00431769 | An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma | completed | Phase 2 | 130 | Janssen-Cilag International NVINDUSTRY | 8 | May 12, 2014 | clinicaltrials |
| NCT01130194 | Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma(MasterPlan) | completed | Phase 2 | 29 | St. Louis UniversityOTHER | 1 | May 12, 2014 | clinicaltrials |
| NCT00069758 | Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | CephalonINDUSTRY | 2 | May 9, 2014 | clinicaltrials |
| NCT00076349 | SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | 66 | CephalonINDUSTRY | 3 | May 9, 2014 | clinicaltrials |
| NCT00392314 | Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. | completed | Phase 2 | 365 | Rambam Health Care CampusOTHER | 1 | May 9, 2014 | clinicaltrials |
| NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 8, 2014 | clinicaltrials |
| NCT00901225 | Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2014 | clinicaltrials |
| NCT01105403 | Exploratory Study on POL6326 in Stem Cell Mobilization | completed | Phase 2 | 21 | Polyphor Ltd.INDUSTRY | 1 | Apr 23, 2014 | clinicaltrials |
| NCT00109967 | CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 71 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2014 | clinicaltrials |
| NCT01220375 | PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma(PAV) | completed | Phase 2 | 44 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00724984 | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma(PCYC-0403) | completed | Phase 1 / Phase 2 | 55 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00847639 | Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma(07-REV) | completed | Phase 2 | 30 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Apr 4, 2014 | clinicaltrials |
| NCT00033267 | CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2014 | clinicaltrials |
| NCT01072773 | Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 133 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 31, 2014 | clinicaltrials |
| NCT02099292 | Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma(Mz-135) | completed | Phase 2 | 103 | Georg Hess, MDOTHER | 0 | Mar 28, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2014source: clinicaltrials